KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Gross Profit: 2014-2025

Historic Gross Profit for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Sep 2025 value amounting to $65.3 million.

  • Aurinia Pharmaceuticals' Gross Profit rose 5.76% to $65.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $236.4 million, marking a year-over-year increase of 22.95%. This contributed to the annual value of $206.9 million for FY2024, which is 28.21% up from last year.
  • Aurinia Pharmaceuticals' Gross Profit amounted to $65.3 million in Q3 2025, which was up 3.81% from $62.9 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Gross Profit ranged from a high of $65.3 million in Q3 2025 and a low of $866,000 during Q1 2021.
  • For the 3-year period, Aurinia Pharmaceuticals' Gross Profit averaged around $50.0 million, with its median value being $48.3 million (2024).
  • Within the past 5 years, the most significant YoY rise in Aurinia Pharmaceuticals' Gross Profit was 49,600.00% (2021), while the steepest drop was 54.15% (2021).
  • Over the past 5 years, Aurinia Pharmaceuticals' Gross Profit (Quarterly) stood at $22.9 million in 2021, then grew by 18.10% to $27.1 million in 2022, then spiked by 46.64% to $39.7 million in 2023, then skyrocketed by 36.81% to $54.3 million in 2024, then grew by 5.76% to $65.3 million in 2025.
  • Its last three reported values are $65.3 million in Q3 2025, $62.9 million for Q2 2025, and $53.9 million during Q1 2025.